Skip to content

New Jersey · Nonprofit

Women of Color In Pharma

Women of Color In Pharma (New Jersey) receives grants from 2 organizations whose IRS filings report $116,150 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($85,000). 1 of them have funded it in more than one year.

Revenue FY2024
$2.9M
Funders on record
2
Grants received
$116k
Net assets
$1.1M
1/2 repeat funderspeak grant-dependency 9%
01What it does

What Women of Color In Pharma does

Mission

To empower women of color in Pharma and the life sciences to excel in their personal and professional development and to transform their pathway and the pathway of others. By creating a nurturing and safe environment for self-reflection and discovery amongst Black and Latina women to foster personal and professional growth that will address a critical gap required to promote innovation and leadership.

As stated on its FY2024 Form 990.

Program

  1. The Organization's activities empower professionals to be effective and impactful, so every voice contributes to a healthier world.

The program described on its FY2025 Form 990.

02The organization over time

The organization over time

Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

100 = 20172017 Revenue 100 ($121k) Expenses 100 ($51k) Net assets 100 ($70k)2018 Revenue 314 ($380k) Expenses 649 ($331k) Net assets 170 ($119k)2019 Revenue 597 ($723k) Expenses 1085 ($553k) Net assets 412 ($289k)2020 Revenue 790 ($957k) Expenses 1853 ($945k) Net assets 429 ($301k)2021 Revenue 1950 ($2.4M) Expenses 3452 ($1.8M) Net assets 1288 ($904k)2022 Revenue 2090 ($2.5M) Expenses 5455 ($2.8M) Net assets 934 ($655k)2023 Revenue 1509 ($1.8M) Expenses 4030 ($2.1M) Net assets 611 ($429k)2024 Revenue 2356 ($2.9M) Expenses 4248 ($2.2M) Net assets 1593 ($1.1M)
'17'18'19'20'21'22'23'24
Revenue (2356)Expenses (4248)Net assets (1593)Peer revenue range

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $302k to $926k (+207%).

$70k
$119k
$315k
$302k
$926k
$713k
$563k
$1.2M
'17'18'19'20'21'22'23'24
Total assetsTotal liabilities

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

2017
2018
2019
2020
2021
2022
2023
2024
ContributionsProgram revenueInvestmentOther

72% of Women of Color In Pharma’s revenue is contributions — more donation-reliant than the typical peer (61% for the typical peer).

This organization
Typical peer · 4,434 orgs

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.

$70k
’17
$49k
’18
$170k
’19
$12k
’20
$602k
’21
−$249k
’22
−$227k
’23
$689k
’24
0.9
months of
reserve

Leadership and staff

The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.

'17'18'19'20'21'22'23'24
Listed6677731110
Joined·+0+3+0+0+0+10+7
No longer listed·0200428
03Who funds it

Who funds it, year by year

2020 → 2023: the base held at 1 funder, grant income fell $85k → $11k.

Funder
'20
'21
'22
'23
total
funders
1
1
1
1

From the IRS filings of Women of Color In Pharma’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

Women of Color In Pharma leans on a few funders — its largest provides 73% of grant income and the top three 100%; half comes from just 1 funder.

the vertical line marks half of all grant income — 1 funder to its left

100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund Women of Color In Pharma.

73%
largest funder
100%
top three
~2
effective funders

Largest funder’s share by year: 2020 100% · 2021 100% · 2022 100% · 2023 100% — broadly stable.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

Women of Color In Pharma draws 100% of its grant income from funders outside New Jersey, across 1 state in all.

DC

In-state vs out-of-state, by year

’20
’21
’22
’23
New Jersey out of state home

Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

04Its place in the field

Against its field

Women of Color In Pharma runs a healthier operating margin than three-quarters of the 4,203 community improvement nonprofits its size.

Operating margin24% · top quartile
Months of reserve0.9mo · bottom quartile
Revenue growth (annualized)57% · top quartile

this organization peer median middle 50% of peers· 4,203 community improvement nonprofits $1M–$10M, FY2024

Organizations like Women of Color In Pharma

Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.

In New Jersey

Nationally

05Profile & governance

Read directly from this organization’s own Form 990, as neutral context.

Governance

9
board members
100%
independent
✓Conflict-of-interest policy✓Whistleblower policy–Document retention✓Board reviewed the 990–Audited financials

Screen this organization

A dated, signed PDF of the compliance screen for Women of Color In Pharma: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.

A paid feature, included from the $75 plan up. Sign in to download.

Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf

Questions and answers

Who funds Women of Color In Pharma?
Women of Color In Pharma (New Jersey) receives grants from 2 organizations whose IRS filings report $116,150 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($85,000). 1 of them have funded it in more than one year.
How many funders does Women of Color In Pharma have?
IRS filings report 2 organizations giving $116,150 in grants to Women of Color In Pharma, 1 of which have funded it in more than one year.
Who is the largest funder of Women of Color In Pharma?
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA is the largest funder on record, with $85,000 in grants. The full list of funders is on this page.
How can an organization like Women of Color In Pharma find more funders?
Start with the funders already giving here, then look at the foundations that back similar organizations in New Jersey. The funding by cause and by state pages list the largest funders for a given area and how to approach them.

These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 2 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing